Breast Cancer — Written Clinical Reasoning

SAQ 1 — HER2-positive breast cancer: neoadjuvant TCHP, KATHERINE, and cardiotoxicity (15 marks, 30 minutes)

Prompt: Outline your staging synthesis, the rationale and expected outcomes of neoadjuvant therapy, the response-adapted adjuvant strategy, the cardiac monitoring plan, and the role of germline genetic testing. Justify each decision with reference to evidence. ^[1]

Model Answer

Step 1 — The staging synthesis (3 marks): ^[1]

This woman has stage IIA (T2 N1 M0) HER2-positive invasive breast cancer — a 3 cm primary (T2) with one suspicious axillary node on ultrasound (clinical N1) and no distant metastases on staging CT (M0). The HER2-positive subtype (ER-negative, PR-negative, HER2 3+ by immunohistochemistry) is driven by ERBB2 gene amplification and was historically the most aggressive breast cancer subtype, with a high propensity for early systemic relapse and brain metastases. The introduction of trastuzumab and the dual HER2 blockade strategy has transformed outcomes, making HER2-positive disease one of the most treatable breast cancer subtypes ^[4].

The key decision point is that her tumour is over 2 cm and clinically node-positive, which makes her an ideal candidate for neoadjuvant systemic therapy rather than upfront surgery. ^[1]

Step 2 — Neoadjuvant therapy: rationale and regimen (5 marks): ^[1]

The standard neoadjuvant regimen for HER2-positive breast cancer over 2 cm or node-positive is docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) for 6 cycles (approximately 18 weeks). The rationale for neoadjuvant therapy in this patient is threefold: ^[1]

1. Downstaging: The 3 cm tumour with an involved node may be converted from mastectomy to breast-conserving surgery if it responds, and the axillary nodal burden may be reduced.
2. Assessing response: The pathologic complete response (pCR) rate with TCHP in HER2-positive disease is approximately 40 to 60 percent. Achieving pCR is a powerful prognostic marker — patients who achieve pCR have event-free survival rates approaching 90 percent at 5 years.
3. Treating micrometastatic disease earlier: Systemic therapy delivered before surgery addresses occult micrometastases while the primary tumour is still in situ, and the immune response to tumour antigens may be more effective. ^[1]

The dual HER2 blockade (trastuzumab plus pertuzumab) is superior to trastuzumab alone in the neoadjuvant setting. Pertuzumab binds a different epitope on the HER2 extracellular domain (domain II, the dimerisation domain) and prevents HER2-HER3 dimerisation, complementing trastuzumab (which binds domain IV). The combination substantially improves the pCR rate compared with trastuzumab alone. The CLEOPATRA trial established the benefit of adding pertuzumab to trastuzumab and docetaxel in the metastatic setting, and dual blockade was extended to the neoadjuvant setting ^[8].

Step 3 — Response-adapted adjuvant strategy (the KATHERINE principle) (4 marks): ^[1]

After neoadjuvant TCHP and surgery, the adjuvant strategy depends on whether the patient achieves a pathologic complete response (pCR): ^[1]

• If pCR (no residual invasive disease in the breast or nodes): Continue trastuzumab to complete a total of 1 year of HER2-directed therapy (the remaining 9 months after surgery). The HERA trial established that 1 year of trastuzumab is the standard duration — 2 years offered no additional benefit ^[4].
• If residual invasive disease: Switch to ado-trastuzumab emtansine (T-DM1) for 14 cycles (approximately 10 months) to complete the year of HER2-directed therapy. The KATHERINE trial demonstrated that T-DM1 reduced the risk of recurrence of invasive breast cancer or death by approximately 50 percent at 3 years compared with continuing trastuzumab (invasive disease-free survival 88.3 percent versus 77.0 percent) ^[5]. This is now the standard of care for HER2-positive patients with residual disease after neoadjuvant therapy.

T-DM1 is an antibody-drug conjugate linking trastuzumab to DM1 (a maytansinoid microtubule inhibitor), delivering cytotoxic therapy selectively to HER2-expressing cells. Its principal toxicities are thrombocytopenia and hepatic enzyme elevation. ^[1]

Step 4 — Cardiac monitoring (2 marks): ^[1]

Both trastuzumab and pertuzumab can cause left ventricular dysfunction, and the anthracycline-free TCHP regimen was partly designed to avoid the additive cardiotoxicity of sequential anthracycline and trastuzumab. Nevertheless, cardiac monitoring is mandatory: ^[1]

• Baseline echocardiogram before starting therapy to establish the LVEF (must be above 50 percent to proceed).
• Serial echocardiography every 3 months during therapy.
• If LVEF drops by 10 percentage points or to below 50 percent: hold HER2-directed therapy, initiate ACE inhibitor and beta-blocker, recheck in 4 to 6 weeks. Trastuzumab-related cardiotoxicity is typically reversible, unlike anthracycline cardiotoxicity which is dose-dependent and largely irreversible. ^[1]

Step 5 — Germline genetic testing (1 mark): ^[1]

Although her tumour is HER2-positive (not triple-negative), she is 52 years old. Germline BRCA testing is not automatically indicated by age alone for HER2-positive disease, but the family history should be taken carefully. If there are features suggestive of hereditary risk (family history of breast or ovarian cancer, Ashkenazi Jewish ancestry, bilateral disease, male breast cancer in the family), she should be referred for genetic counselling and testing. If a BRCA mutation is found, she would be eligible for adjuvant olaparib per the OlympiA trial, provided the tumour is HER2-negative — but since her tumour is HER2-positive, olaparib is not currently indicated ^[7]. The testing would still be important for cascade testing of family members and ovarian cancer risk management.

Step 6 — Communication (1 mark): ^[1]

I would explain to this woman that her cancer type — HER2-positive — was once the most aggressive form of breast cancer but is now one of the most treatable, thanks to targeted therapies that attack the HER2 protein. I would describe the neoadjuvant approach: chemotherapy and targeted therapy first to shrink the tumour and test its sensitivity, then surgery, then further targeted therapy based on the response. I would be honest about the side effects — hair loss, fatigue, neuropathy, the small risk of heart effects — and about the uncertainty of the response. I would introduce the cancer nurse coordinator, offer psychological support, and document the shared decision-making. ^[1]